Valuation: Everest Organics Limited

Market Cap 1.98B 20.75M 18.13M 16.65M 15.53M 29.44M 29.93M 200M 77.7M 969M 77.92M 76.23M 3.34B P/E 2024
675x
P/E 2025 -190x
Enterprise Value 2.39B 25.08M 21.92M 20.13M 18.77M 35.58M 36.18M 242M 93.92M 1.17B 94.18M 92.14M 4.04B EV / Sales 2024
0.75x
EV / Sales 2025 1.79x
Free-Float
23.02%
Yield 2024 *
-
Yield 2025 -
1 day+7.43%
1 week+6.58%
Current month+8.33%
1 month+15.58%
3 months+17.48%
6 months-46.39%
Current year-46.53%
1 week 245
Extreme 245
284
1 month 230
Extreme 230
284
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 101
Extreme 101
536.4
5 years 95
Extreme 95
536.4
10 years 28.65
Extreme 28.65
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 28/09/2015
Director TitleAgeSince
Director/Board Member 71 13/11/2024
Director/Board Member 47 29/09/2007
Director/Board Member 48 30/07/2014
Change 5-day change 1-year change 3-year change Capi.($)
+7.43%+6.58%-21.60%+165.02% 25.68M
+1.81%+1.60%+13.40%+84.45% 47.15B
-2.54%+3.72%+65.71%+113.61% 37.94B
+0.15%+0.28%-3.35%+45.56% 12.35B
+3.71%+1.72%+14.13%+97.20% 11.52B
+2.33%-1.72%+32.73%+121.98% 8.93B
+0.08%-1.14%+18.59%+44.72% 7.14B
+0.71%+1.75%+53.59%-7.09% 7.02B
+0.68%+1.12%+23.97%+235.28% 6.51B
+6.55%+16.24%-23.92%+16.83% 5.98B
Average +2.09%+2.83%+17.33%+91.76% 14.46B
Weighted average by Cap. +0.72%+3.13%+28.08%+89.72%

Financials

2024 2025
Net sales 1.98B 20.8M 18.18M 16.69M 15.56M 29.51M 30.01M 201M 77.88M 971M 78.1M 76.41M 3.35B 1.6B 16.8M 14.68M 13.48M 12.57M 23.83M 24.24M 162M 62.91M 785M 63.09M 61.72M 2.7B
Net income 1.39M 14.62K 12.78K 11.73K 10.94K 20.74K 21.09K 141K 54.75K 683K 54.9K 53.71K 2.35M -12.9M -136K -118K -109K -101K -192K -196K -1.31M -507K -6.33M -509K -498K -21.81M
Net Debt 570M 5.98M 5.23M 4.8M 4.48M 8.49M 8.63M 57.8M 22.4M 279M 22.47M 21.98M 963M 412M 4.33M 3.78M 3.48M 3.24M 6.14M 6.25M 41.85M 16.22M 202M 16.26M 15.91M 697M
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
355
Date Price Change Volume
03/07/26 270.45 +7.43% 5,524
02/07/26 ₹251.75 +0.70% 21,132
01/07/26 ₹250.00 +0.14% 1,124
30/06/26 ₹249.65 -1.62% 2,659
29/06/26 ₹253.75 -4.64% 628
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock